HUE056356T2 - Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére - Google Patents

Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére

Info

Publication number
HUE056356T2
HUE056356T2 HUE16869342A HUE16869342A HUE056356T2 HU E056356 T2 HUE056356 T2 HU E056356T2 HU E16869342 A HUE16869342 A HU E16869342A HU E16869342 A HUE16869342 A HU E16869342A HU E056356 T2 HUE056356 T2 HU E056356T2
Authority
HU
Hungary
Prior art keywords
pyrido
pyrazine
tetrahydro
ones
treatment
Prior art date
Application number
HUE16869342A
Other languages
English (en)
Inventor
James Barrow
Glen Ernst
Dominique Swinnen
Florian Montel
Sabine Defays
Yifang Huang
Leon Pablo De
Michael Steven Poslusney
Original Assignee
Lieber Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lieber Inst Inc filed Critical Lieber Inst Inc
Publication of HUE056356T2 publication Critical patent/HUE056356T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE16869342A 2015-11-25 2016-11-25 Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére HUE056356T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260067P 2015-11-25 2015-11-25

Publications (1)

Publication Number Publication Date
HUE056356T2 true HUE056356T2 (hu) 2022-02-28

Family

ID=58763706

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16869342A HUE056356T2 (hu) 2015-11-25 2016-11-25 Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére

Country Status (8)

Country Link
US (2) US10934283B2 (hu)
EP (1) EP3380471B8 (hu)
CA (1) CA3006189C (hu)
DK (1) DK3380471T3 (hu)
ES (1) ES2893613T3 (hu)
HU (1) HUE056356T2 (hu)
PL (1) PL3380471T3 (hu)
WO (1) WO2017091818A1 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53944A (fr) 2014-08-28 2021-08-25 Asceneuron Sa Inhibiteurs de la glycosidase
ES2879351T3 (es) 2016-02-25 2021-11-22 Asceneuron Sa Sales de derivados de piperazina obtenidas por adición de ácidos
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3419971B1 (en) 2016-02-25 2022-04-20 Asceneuron SA Glycosidase inhibitors
WO2017144639A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
WO2019037861A1 (en) * 2017-08-24 2019-02-28 Asceneuron S.A. ANNOTATED GLYCOSIDASE INHIBITORS
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
GB0130696D0 (en) 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
WO2005016344A1 (en) 2003-08-14 2005-02-24 Pfizer Limited Piperazine derivatives for the treatment of hiv infections
RU2518483C2 (ru) 2007-01-31 2014-06-10 Биал-Портела Энд Ка, С.А. Режим дозирования ингибиторов комт
ES2606395T3 (es) 2008-04-18 2017-03-23 Intec Pharma Ltd. Administración de fármacos gastrorretentivos para carbidopa/levodopa
KR101720824B1 (ko) * 2010-03-04 2017-03-28 머크 샤프 앤드 돔 코포레이션 카테콜 o-메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도
GB201004372D0 (en) 2010-03-16 2010-04-28 Almac Sciences Scotland Ltd Compounds for purification
US20140186280A1 (en) 2010-08-13 2014-07-03 Varinel Inc Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof
DK2620436T3 (en) * 2010-09-24 2018-07-30 Shionogi & Co Substituted polycyclic carbamoylpyridone derivative prodrug
CA2975401A1 (en) 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions

Also Published As

Publication number Publication date
WO2017091818A1 (en) 2017-06-01
US20210139479A1 (en) 2021-05-13
EP3380471B1 (en) 2021-09-08
US10934283B2 (en) 2021-03-02
DK3380471T3 (da) 2021-10-11
EP3380471A4 (en) 2019-05-15
US20180305354A1 (en) 2018-10-25
PL3380471T3 (pl) 2021-12-20
CA3006189A1 (en) 2017-06-01
EP3380471A1 (en) 2018-10-03
ES2893613T3 (es) 2022-02-09
EP3380471B8 (en) 2022-01-19
CA3006189C (en) 2023-12-19

Similar Documents

Publication Publication Date Title
HK1244280B (zh) 用於治療感染性疾病的吡嗪化合物
IL263484A (en) Pyrimidine-2-ylamino-h1-pyrazoles as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
HK1248609A1 (zh) 用於治療異常不自主運動障礙的方法
EP3349760A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
HUE056356T2 (hu) Tetrahidro-8H-pirido[1,2-a]pirazin-8-on vegyületek, mint COMT inhibitorok neurodegeneratív rendellenességek kezelésére
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
IL262348A (en) Preparations for the treatment of excessive radiation disorders
EP3331550A4 (en) METHOD FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES
EP3283655A4 (en) Methods for treating myeloproliferative disorders
EP3329018A4 (en) Methods for treating hepcidin-mediated disorders
HUE051654T2 (hu) Készítmény akné kezelésére
SG11201708181RA (en) Methods for the treatment of inflammatory disorders
EP3200795A4 (en) Use of agents for treating fat-related disorders
HK1250624A1 (zh) 用於治療心血管障礙的方法
EP3507277B8 (en) Hydroxynorketamine derivatives for the treatment of disorders
GB201521543D0 (en) Methods for the treatment of inflammatory disorders
GB201513993D0 (en) Methods for the treatment of inflammatory disorders
GB201513345D0 (en) Methods for the treatment of Inflammatory disorders
GB201507113D0 (en) Methods for the treatment of inflammatory disorders
GB201506419D0 (en) Methods for the treatment of inflammatory disorders
GB201506229D0 (en) Methods For the Treatment Of Inflammatory Disorders
PL3273997T3 (pl) Kompozycja do leczenia nieżytu nosa
PT3524255T (pt) Composição para o tratamento do acne
GB201521542D0 (en) Methods for the treatment of cardiovascular disorders
GB201513991D0 (en) Methods for the treatment of cardiovascular disorders